Full-Time

Senior Scientist

Assay Development, Reagents

Glyphic Biotechnologies

Glyphic Biotechnologies

11-50 employees

Next-generation protein sequencing platform provider

Compensation Overview

$111.7k - $161.9k/yr

+ Stock Options

Berkeley, CA, USA

In Person

Bachelor's, Master's, PhD

Category
Biology & Biotech
Required Skills
Biophysics
Chemical Biology
Biochemistry

Get referred to Glyphic Biotechnologies

See people who can refer or advise you

Requirements
  • Degree in Biochemistry, Chemical Biology, Biophysics, Biomedical Engineering, or an equivalent field; PhD / MS / BS with 4+ / 6+ / 8+ years of relevant experience for Senior Scientist or PhD / MS / BS with 2+ / 4+ / 6+ years of relevant experience for Scientist II; Proven bench expertise in reagent development or analytical science with hands-on experience across biochemical characterization techniques and ability to establish operating bounds and guard bands for critical reagent and process parameters; Deep understanding of reagent formulation principles and their influence on stability and functional performance with practical experience across the full reagent development cycle including formulation, stability studies, and QC method development; Experience working with chemically reactive or environmentally sensitive compounds including materials susceptible to degradation by oxygen, humidity, or light, with appropriate handling, storage, and stability assessment practices; Strong experimental design skills with the ability to plan and execute DOE-informed studies and interpret results against specifications; Experience developing reagents for multistep, integrated assay workflows involving multiple handoff points or checkpoints, including multi-omics or multi-component platforms; Experience establishing and maintaining robust SOPs for end-to-end integrated workflows with consistent capture of key experimental variables, reagents, and process conditions enabling cross-functional traceability and correlation with downstream data and performance; Excellent problem-solving skills and meticulous attention to detail; Strong written and verbal communication skills with ability to work effectively with colleagues across diverse scientific and technical backgrounds; Comfortable navigating a fast-paced, resource-constrained environment with shifting priorities.
Responsibilities
  • Lead assay reagent development activities, including formulation, characterization, and optimization, for components used in ProSE single-molecule expansion and library preparation workflows, including enzymes, oligos, beads, and solvents; The materials in scope extend beyond standard biological reagents to include chemically reactive compounds and environmentally sensitive materials susceptible to degradation by oxygen, humidity, light, and temperature fluctuations, requiring a chemistry-aware approach to formulation, handling, and storage; Characterize reagent performance using design-of-experiments approaches, systematically varying formulation conditions, buffer composition, excipients, and process parameters to establish operating bounds and define product specifications; Design and execute experiments to evaluate reagent performance in end-use assay configurations; develop a mechanistic understanding of how reagent composition, lot variability, and environmental sensitivity impact expansion assay outcomes; Design and execute reagent storage stability studies under accelerated and real-time conditions; develop stability-indicating assays; interpret results against established product specifications and flag out-of-spec trends proactively; Build and implement a QC and control framework for platform reagents, including acceptance criteria, lot release protocols, and QC assay development, to support reliable, consistent supply to the Assay team; Develop, qualify, and transfer QC test methods for reagent characterization and lot release, including HPLC, fluorescence-based functional assays, and physical characterization methods; set product, process, and incoming material acceptance criteria in collaboration with Assay and cross-functional partners; Qualify each reagent lot prior to use in multi-cycle or key opinion leader runs; execute hands-on QC testing encompassing physical, chemical, and functional characterization; gate go/no-go decisions on input materials and maintain provenance records for high-stakes runs; Maintain batch records and quality documentation in accordance with internal standards; Establish and maintain SOPs for assay reagents and integrated workflows; systematically investigate lot-to-lot variability and failure modes; troubleshoot deviations and lead root cause analysis and corrective action; Guard-band critical reagent components and workflow steps to establish the operating bounds of new protocols and define tolerance limits for expansion assay parameters; Forecast and maintain end-to-end reagent inventory for SOP-level runs, ensuring the Assay team has qualified materials available on schedule for integration runs and platform demonstrations; Partner with the Automation team to implement and qualify reagent-dependent assay steps on work cell or Hamilton-based platforms; qualify liquid-handling methods against reagent specifications; Analyze experimental data using statistical methods; synthesize results to identify trends and trace them to upstream reagent, process, or formulation variables; communicate findings through technical reports and presentations, and maintain comprehensive documentation to ensure reproducibility and preserve institutional knowledge;
Desired Qualifications
  • Background in proteomics reagents, protein modification chemistry, peptide-oligonucleotide conjugates, or single-molecule assay components; Experience with automation platforms for liquid handling (for example Hamilton, ThermoFisher, Agilent) and protocol validation on automated workcells;
Glyphic Biotechnologies

Glyphic Biotechnologies

View

Glyphic Biotechnologies is advancing proteomics by building a next-generation protein sequencing platform. The core product is designed to reveal detailed information about proteins, helping researchers and medical institutions gain new insights into biology and disease. The platform supports sequencing services for researchers and may be licensed to other organizations, generating revenue from service fees and licensing agreements. Unlike many competitors that focus on smaller-scale tools, Glyphic emphasizes a first-of-its-kind sequencing capability for proteins, along with diverse deployment options (serving research labs directly and via licensing). The company's goal is to enable deeper understanding of bodily functions through protein data and to bring its sequencing technology to broader use in the life sciences through services and licensing deals.

Company Size

11-50

Company Stage

Early VC

Total Funding

$43M

Headquarters

New York City, New York

Founded

2021

Get referred to Glyphic Biotechnologies

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Glyphic raised $38 million by September 2025, extending runway for platform development.
  • Glyphic posted multiple 2026 hires in Berkeley, signaling active buildout and execution.
  • NIH and Bakar Labs visibility plus 2025 patent publications validate technical momentum.

What critics are saying

  • Glyphic still sells no commercial platform, so revenue depends on unproven hardware delivery in 2026.
  • Protein sequencing must beat mass spectrometry, or customers ignore Glyphic’s expensive workflow.
  • If ProSE misses accuracy or throughput targets, the 2025 Series A becomes a financing trap.

What makes Glyphic Biotechnologies unique

  • Glyphic’s ProSE sequences proteins de novo, one molecule at a time, without databases.
  • Glyphic claims single-molecule discrimination of all 20 amino acids and PTMs in Berkeley, 2026.
  • Glyphic holds issued patents and a 2025 nanopore peptide-sequencing filing around core chemistry.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Unlimited Paid Time Off

Commuter Benefits

Paid Maternity and Paternity Leave

Home Office Stipend

Wellness Program

Company Equity

Employee Stock Purchase Plan

Growth & Insights and Company News

Headcount

6 month growth

6%

1 year growth

0%

2 year growth

3%
Labs of Latvia
Dec 3rd, 2024
Latvian LongeVC invests in US startup Glyphic Biotechnologies

Founded in New York in 2021 by Daniel Estandian and Joshua Yang, Glyphic Biotechnologies is developing a protein sequencing platform that uses single-molecule technology to analyze the sequence of each protein in a complex protein mixture.

BioPharmaTrend
Nov 25th, 2024
LongeVC Invests in Glyphic Biotechnologies

LongeVC has invested in Glyphic Biotechnologies, which is developing single-molecule protein sequencing technology. This innovation surpasses mass spectrometry by enabling precise sequencing of individual proteins in complex mixtures, enhancing protein analysis and broadening applications in drug discovery and diagnostics. The proteomics market, valued at over $30 billion, is set for growth with such advancements. This aligns with LongeVC's mission to support transformative healthcare technologies.

U.S. Securities and Exchange Commission
Feb 21st, 2024
SEC FORM D

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.The reader should not assume that the information is accurate and complete.

Johnson & Johnson Innovation
Apr 5th, 2023
Awardees of the BLUE KNIGHT™ Resident QuickFire Challenge Strive Toward Inflection Points | Johnson & Johnson Innovation

By: Rachel Rath, Director, BARDA Alliance, Johnson & Johnson Innovation – JLABS & Ashim Subedee, Director, DRIVe Catalyst Office, BARDA

Bakar Labs
Jan 31st, 2023
Glyphic Biotechnologies Wins $409K SBIR Grant From NIH - Bakar Labs

Congratulations to Glyphic Biotechnologies! NIH recently reported the company had been awarded a $409 SBIR grant for their project "Single-molecule protein sequencing by iterative isolation and identification of N-terminal amino acids." The company is developing and commercializing technology to sequence proteins — instead of DNA. They're hiring!